Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy.
Nat Commun. 2020 Jan 31;11(1):661. doi: 10.1038/s41467-020-14471-1.
Nat Commun. 2020.
PMID: 32005826
Free PMC article.
Clinical Trial.